降脂功效的伐。

文章的细节

引用
复制到剪贴板

亚当斯SP, Sekhon党卫军,赖特JM

降脂功效的伐。

科克伦数据库系统启2014年11月21日;(11):CD010254。cd010254.pub2 doi: 10.1002/14651858.。

PubMed ID
25415541 (在PubMed
]
文摘

背景:普伐他汀类药物是最有效的,目前广泛的规定。因此重要的是要知道的量大小伐对血脂的影响。目的:主要目标量化的影响不同剂量的伐血清总胆固醇、低密度脂蛋白(LDL)胆固醇、高密度脂蛋白(HDL)胆固醇,non-HDL-cholesterol和甘油三酯在参与者,没有心血管疾病的证据。二级目标量化的影响的可变性不同剂量的伐。量化取款由于副作用(WDAEs)随机安慰剂对照试验。必威国际app搜索方法:我们搜索Cochrane中央注册的对照试验(中央)10的12个问题,2014年Cochrane图书馆、MEDLINE(1946年至2014年10月第5周),EMBASE(1980年至2014年星期44),网络科学的核心集合(1970年至2014年11月5日)和生命现象引文索引(1969年至2014年10月31日)。没有语言的限制。选择标准:随机对照和不受控制的前后试验评估不同的剂量反应固定剂量的伐血脂在3到12周的时间。数据收集和分析:两个评论作者独立评估合格标准为研究包括和提取数据。WDAEs信息收集的安慰剂对照试验。 MAIN RESULTS: One-hundred and eight trials (18 placebo-controlled and 90 before-and-after) evaluated the dose-related efficacy of rosuvastatin in 19,596 participants. Rosuvastatin 10 to 40 mg/day caused LDL-cholesterol decreases of 46% to 55%, when all the trials were combined using the generic inverse variance method. The quality of evidence for these effects is high. Log dose-response data over doses of 1 to 80 mg, revealed strong linear dose-related effects on blood total cholesterol, LDL-cholesterol and non-HDL-cholesterol. When compared to atorvastatin, rosuvastatin was about three-fold more potent at reducing LDL-cholesterol. There was no dose-related effect of rosuvastatin on blood HDL-cholesterol, but overall, rosuvastatin increased HDL by 7%. There is a high risk of bias for the trials in this review, which would affect WDAEs, but unlikely to affect the lipid measurements. WDAEs were not statistically different between rosuvastatin and placebo in 10 of 18 of these short-term trials (risk ratio 0.84; 95% confidence interval 0.48 to 1.47). AUTHORS' CONCLUSIONS: The total blood total cholesterol, LDL-cholesterol and non-HDL-cholesterol-lowering effect of rosuvastatin was linearly dependent on dose. Rosuvastatin log dose-response data were linear over the commonly prescribed dose range. Based on an informal comparison with atorvastatin, this represents a three-fold greater potency. This review did not provide a good estimate of the incidence of harms associated with rosuvastatin because of the short duration of the trials and the lack of reporting of adverse effects in 44% of the placebo-controlled trials.

DrugBank数据引用了这篇文章

药物
伐